By Sherri Oslick —

About
Court Report:  Each week we will report briefly on recently filed
biotech and pharma cases, and a few interesting cases will be selected
for periodic monitoring.

Cephalon Inc. et al. v. Actavis Group et al.
1:09-cv-00940; filed December 8, 2009 in the
District Court of Delaware

• Plaintiffs: 
Cephalon Inc.; Cephalon France
• Defendants: 
Actavis Group; Actavis Pharma Manufacturing Pvt Ltd.; Actavis Inc.

Infringement of U.S. Patent Nos. RE37,516
("Acetamide Derivative Having Defined Particle Size," issued January
15, 2002) and 7,132,570 ("Method for the Production of Crystalline Forms
of Optical Enantiomers of Modafinil," issued November 7, 2006) following a
Paragraph IV certification as part of Actavis' filing of an ANDA to manufacture
a generic version of Cephalon's Nuvigil® (armodafinil, used to improve
wakefulness in patients with excessive sleepiness associated with obstructive
sleep apnea/hypopnea syndrome, narcolepsy, and shift work sleep disorder).  View the complaint here.

Pfizer Inc. et al. v. Dr. Reddy's Laboratories Ltd. et al.
1:09-cv-00943; filed December 8, 2009 in the
District Court of Delaware

• Plaintiffs:  Pfizer Inc.; Pfizer Ireland Pharmaceuticals; Warner-Lambert Co.;
Warner-Lambert Co. LLC
• Defendants:  Dr. Reddy's Laboratories Ltd.; Dr. Reddy's Laboratories Inc.

Infringement of U.S. Patent No. 5,969,156
("Crystalline [R- (R*,R*)]-2-(4
Fluorophenyl)-β,δ-dihydroxy-5-(1-methylethyl)- 3-phenyl-4-[(phenylamino)carbonyl]-1H-pyrrole-1-heptanoic
acid hemi calcium salt (atorvastatin)," issued October 19, 1999) following
a Paragraph IV certification as part of Dr. Reddy's filing of an ANDA to
manufacture a generic version of Pfizer's Lipitor® (atorvastatin calcium, used
to treat high cholesterol and heart disease).  View the complaint here.

Galderma Laboratories, L.P. et al. v. Perrigo Co. et al.
3:09-cv-02322; filed December 4, 2009 in the
Northern District of Texas

• Plaintiffs: 
Galderma Laboratories, L.P.; Galderma S.A.; Dermalogix Partners Inc.
• Defendants: 
Perrigo Co.; Perrigo Israel Pharmaceuticals Ltd.

Infringement of U.S. Patent No. 5,972,920
("Formulation Containing a Carrier, Active Ingredient, and Surfactant for
Treating Skin Disorders," issued October 26, 1999) following a Paragraph
IV certification as part of Perrigo's filing of an ANDA to manufacture a
generic version of Galderma's Clobex® (clobetasol propionate, used for the
treatment of moderate to severe plaque psoriasis).  View the complaint here.